Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2002

View Archived Issues

Oxxon Pharmaccines licenses MVA technology from Alpharma

ProdiGene successfully expresses SIV subunit vaccine

Phase I/II trials of gene therapy cancer vaccine expanded

Maxim describes discovery, SAR and biological activity of apoptosis inducers at ACS meeting

Selective metabotropic glutamate mglu2 receptor allosteric potentiators designed at Lilly

Small-molecule Tie-2 kinase inhibitor exerts antiangiogenic activity in vitro and in vivo

Synthetic antimicrotubule agent related to hemiasterlin displays excellent pharmacological profile

PD-205520, an EGF receptor tyrosine kinase inhibitor, undergoes toxicity testing

Second-generation semisynthetic epothilone analogue enters phase I based on preclinical data

Potent and selective MRP1 inhibitors considered promising clinical candidates

Allos licenses N-Gene's chemoprotective agent BGP-15

Lip'ral technology completes pilot clinical study

Long-term survival findings reported for Multikine in head and neck cancer

E.U. approval for Dynastat in postoperative pain

Sloan-Kettering identifies novel antitumor macrocycles

TLK-286 enters phase II in breast cancer

Approvable letter issued for Xyrem in cataplexy

Study confirms equivalent efficacy for MT-100 and Imitrex in treatment of migraine

First patients enrolled in SAIK-MS phase II trial in multiple sclerosis

Phase Ib of TNFerade in solid tumors completes enrollment

ISTA to proceed with Vitrase NDA filing

Chemokine CCR3 receptor antagonists for immune, inflammatory disorders patented by Celltech

Prodrugs of betulinic acid or derivatives designed for the treatment of tumors, HIV

GABA-A receptor ligands specifically claimed for cognition disorders in recent patent

New Agouron compounds and methods for treating beta-amyloid-mediated conditions

Kitasato Institute reports development of antiinflammatory pseudoerythromycin derivatives

Preparation and use of NK1 receptor antagonists reported by Roche